|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0026764,
umls-concept:C0036667,
umls-concept:C0046319,
umls-concept:C0052416,
umls-concept:C0105770,
umls-concept:C0312418,
umls-concept:C0392756,
umls-concept:C1176309,
umls-concept:C1514526,
umls-concept:C2349975
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2008-7-23
|
|
pubmed:abstractText |
Beta-catenin, the key protein in canonical Wingless/int (Wnt) pathway, degrades via ubiquitin-proteasome pathway. Recently, it proved important roles in the proliferation of myeloma cells. But little is known about whether cytoplasmic beta-catenin content is associated with myeloma cell's sensitivity to Bortezomib. We examined the constitutive expression of beta-catenin in five myeloma cell lines and primary cells from patients. Meanwhile, the effect of Bortezomib combined with arsenic trioxide (As(2)O(3))/2-methoxyestradiol (2ME2) on beta-catenin accumulation, myeloma cells' survival, apoptosis and their sensitivity to Bortezomib were also investigated. Our study proved that beta-catenin protein levels are negatively associated with myeloma cells' sensitivity to Bortezomib. As(2)O(3)/2ME2 can reduce cytoplasmic beta-catenin accumulation after proteasome inhibition and enhance myeloma cells' sensitivity to Bortezomib. This will preliminarily help to optimize the new therapeutic regimens for MM treatment in the future.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-methoxyestradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Arsenicals,
http://linkedlifedata.com/resource/pubmed/chemical/Boronic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/CTNNB1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Oxides,
http://linkedlifedata.com/resource/pubmed/chemical/Proteasome Endopeptidase Complex,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrazines,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Small Interfering,
http://linkedlifedata.com/resource/pubmed/chemical/arsenic trioxide,
http://linkedlifedata.com/resource/pubmed/chemical/beta Catenin,
http://linkedlifedata.com/resource/pubmed/chemical/bortezomib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0145-2126
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1674-83
|
|
pubmed:meshHeading |
pubmed-meshheading:18485479-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18485479-Apoptosis,
pubmed-meshheading:18485479-Arsenicals,
pubmed-meshheading:18485479-Blotting, Western,
pubmed-meshheading:18485479-Boronic Acids,
pubmed-meshheading:18485479-Cell Proliferation,
pubmed-meshheading:18485479-Drug Therapy, Combination,
pubmed-meshheading:18485479-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:18485479-Estradiol,
pubmed-meshheading:18485479-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:18485479-Humans,
pubmed-meshheading:18485479-Multiple Myeloma,
pubmed-meshheading:18485479-Oxides,
pubmed-meshheading:18485479-Proteasome Endopeptidase Complex,
pubmed-meshheading:18485479-Pyrazines,
pubmed-meshheading:18485479-RNA, Messenger,
pubmed-meshheading:18485479-RNA, Small Interfering,
pubmed-meshheading:18485479-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:18485479-Tumor Cells, Cultured,
pubmed-meshheading:18485479-beta Catenin
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
|
|
pubmed:affiliation |
Department of Hematology, the Second Affiliated Hospital to the Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.
|
|
pubmed:publicationType |
Journal Article
|
